C07K 16/2824
Against cd58
Official title: {against CD58}
C07K16/2824 (Against cd58) appears on 11 US grants and 24 published applications in this corpus.
Search patents in C07K- Granted patents
- 11
- Published applications
- 24
- Assignees
- 22
- Inventors
- 61
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 3 |
| 2003 | 0 | 1 |
| 2004 | 1 | 3 |
| 2005 | 0 | 0 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 0 | 2 |
| 2022 | 0 | 2 |
| 2023 | 1 | 2 |
| 2024 | 0 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Trispecific binding molecules against BCMA and uses thereof12 May 2026US 12,624,118 B2Novartis AG
- CD19 binding molecules and uses thereof11 Feb 2025US 12,221,481 B2Novartis AG
- Anti-Ly6G6D antibodies and methods of use19 Dec 2023US 11,845,799 B2Genentech, Inc.
- Compositions and methods for biological remodeling with frozen particle compositions10 Dec 2013US 8,603,495 B2The Invention Science Fund I, LLC
- Method for treating or preventing sclerotic disorders using CD-2 binding agents28 Dec 2010US 7,858,095 B2Astellas US LLC
- Engineered mesenchymal stem cell and use thereof14 May 2026US 2026/0130944 A1Tsinghua University
- Cd19 binding molecules and uses thereof10 Jul 2025US 2025/0223359 A1Novartis AG
- Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies3 Jul 2025US 2025/0215081 A1Novartis AG
- Compositions and methods for modulating cancer immune fitness5 Sep 2024US 2024/0294643 A1Massachusetts Institute of Technology
- Anti-ly6g6d antibodies and methods of use13 Jun 2024US 2024/0190966 A1Genentech, Inc.
Most cited
By later US patents
- Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction67US 6,162,432 ABiogen, Inc. · 2000
- Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand15US 6,451,305 B1Dana-Farber Cancer Institute, Inc. · 2002
- Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction14US 7,323,171 B2Astellas US LLC · 2008
- Purification of LFA-310US 5,190,859 ADana-Farber Cancer Institute, Inc. · 1993
- Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction6US 6,764,681 B2Biogen, Inc. · 2004